What is CellFE?
CellFE operates at the intersection of biotechnology and advanced manufacturing, specializing in microfluidic-based gene editing solutions. Its flagship product, the Ryva Mechanoporation System, serves as a cornerstone for researchers and developers aiming to streamline the production of complex cell therapies. By focusing on the mechanoporation process, CellFE provides a scalable, cost-effective alternative to traditional viral-based delivery methods. This technological edge allows the company to support innovators in the life sciences sector, effectively lowering the barrier to entry for high-quality, affordable patient treatments. As the industry shifts toward more personalized medicine, CellFE's infrastructure-focused approach positions it as a critical enabler for the next generation of curative therapies.
How much funding has CellFE raised?
CellFE has raised a total of $22M across 1 funding round:
Series A
$22M
Series A (2023): $22M with participation from Dynamk Capital, Cota Capital, and Merck Ventures
Key Investors in CellFE
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise.
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in transformational ideas and early-stage technologies that have the potential to impact core business areas.
What's next for CellFE?
With this latest infusion of capital, CellFE is poised to transition from its current development phase into a broader commercialization strategy. The company is expected to prioritize the expansion of its manufacturing capabilities and the further refinement of the Ryva Mechanoporation System to meet increasing demand from global research institutions and clinical developers. By leveraging the expertise of its strategic backers, CellFE will likely focus on deepening its market penetration within the cell therapy ecosystem. The roadmap ahead involves scaling operations to ensure that its gene editing tools become the industry standard for efficient, scalable, and accessible therapeutic production, ultimately driving long-term value for both the company and the patients who rely on these life-saving innovations.
See full CellFE company page
